Interestingly, the pro-angiogenic effect of FGF-1 and FGF-2 besides the VEGF–VEGFR2 axis was already demonstrated and combination of the pan-FGFR inhibitor SSR128129E with DC101 in mouse models of pancreatic cancer yielded an additive therapeutic effect47. The gene discussed is KDR; the disease is familial pancreatic carcinoma.